Latest On PTC Therapeutics, Inc (PTCT):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-26 01:04 EST | News | PTC Therapeutics: Rare Disease Specialist's Stock In Danger Of Slipping Further | N/A |  |
| 2023-05-24 20:54 EST | News | Reata adds 21% as PTC’s Friedreich's ataxia drug fails Phase 3 trial | N/A | |
| 2023-05-24 06:28 EST | News | PTC Therapeutics plummets 22% after Friedreich's ataxia asset fails in phase 3 | N/A | |
| 2023-05-24 06:28 EST | News | PTC abandons preclinical gene therapy programs, cuts staff; CFO departs | N/A | |
| 2023-05-17 21:06 EST | News | PTC Therapeutics' metabolic disorder drug sepiapterin meets main goal in phase 3 trial | N/A | |
About PTC Therapeutics, Inc (PTCT):
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is read more... also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
General
- Name PTC Therapeutics, Inc
- Symbol PTCT
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 959
- Fiscal Year EndDecember
- IPO Date2013-06-20
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.ptcbio.com
Valuation
- Price/Sales (Trailing 12 Mt.) 10.14
- Price/Book (Most Recent Quarter) 8.53
- Enterprise Value Revenue 9
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$6.25
- Next Year EPS Estimate -$3.56
- Next Quarter EPS Estimate -$1.32
- Profit Margin -115%
- Operating Margin -90%
- Return on Assets -11%
- Return on Equity -81%
- Revenue 380.77 million
- Earnings Per Share -$4.10
- Revenue Per Share $5.77
- Gross Profit -62219000
- Quarterly Earnings Growth 23.2%
Highlights
- Market Capitalization 3.91 billion
- EBITDA -125162000
- PE Ratio -5.67
- PEG Ratio 0.81
- Analyst Target Price $61.3
- Book Value Per Share $6.91
Share Statistics
- Shares Outstanding 70.32 million
- Shares Float 63.7 million
- % Held by Insiders 291%
- % Held by Institutions 106.46%
- Shares Short 4.77 million
- Shares Short Prior Month 4.01 million
- Short Ratio 8.11
- Short % of Float 7%
- Short % of Shares Outstanding 7%
Technicals
- Beta 0.99
- 52 Week High $70.82
- 52 Week Low $37.21
- 50 Day Moving Average 58.99
- 200 Day Moving Average 57.85
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
PTC Therapeutics, Inc (PTCT) Dividend Calendar:
PTC Therapeutics, Inc (PTCT) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
PTC Therapeutics, Inc (PTCT) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
PTC Therapeutics, Inc (PTCT) Chart:
PTC Therapeutics, Inc (PTCT) News:
Below you will find a list of latest news for PTC Therapeutics, Inc (PTCT) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
PTC Therapeutics, Inc (PTCT) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest PTCT Trades:
PTC Therapeutics, Inc (PTCT) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-29 | 8-K (Current report) | |
| 2020-10-29 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-07 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-07 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-17 | CT ORDER (Confidential treatment order) | |
| 2020-08-21 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-21 | 8-K (Current report) | |
| 2020-08-11 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-11 | 8-K (Current report) | |
| 2020-08-10 | S-3ASR (Automatic shelf registration statement of securities of well-known seasoned issuers) | |
| 2020-08-07 | 8-K (Current report) | |
PTC Therapeutics, Inc (PTCT) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of PTC Therapeutics, Inc (PTCT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 291%
Institutional Ownership: 10646%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-11-04 | Christine Marie Utter | SVP, Finance & CAO | Buy | 688.00 | 30.86 | 21,231.68 | 10,250.00 | |
| 2020-11-04 | Christine Marie Utter | SVP, Finance & CAO | Buy | 1,567.00 | 30.86 | 48,357.62 | 11,129.00 | |
| 2020-11-04 | Christine Marie Utter | SVP, Finance & CAO | Buy | 2,500.00 | 18.01 | 45,025.00 | 12,062.00 | |
| 2020-11-04 | Stuart Walter Peltz | Chief Executive Officer | Sell | 11,037.00 | 60.00 | 662,220.00 | 12,178.00 | |
| 2020-11-04 | Christine Marie Utter | SVP, Finance & CAO | Buy | 2,656.00 | 33.02 | 87,701.12 | 12,218.00 | |
| 2020-11-04 | Stuart Walter Peltz | Chief Executive Officer | Buy | 500.00 | 12.64 | 6,320.00 | 12,678.00 | |
| 2020-11-04 | Stuart Walter Peltz | Chief Executive Officer | Buy | 1,575.00 | 11.23 | 17,687.25 | 13,753.00 | |
| 2020-11-04 | Stuart Walter Peltz | Chief Executive Officer | Buy | 2,362.00 | 11.23 | 26,525.26 | 14,540.00 | |
| 2020-11-04 | Stuart Walter Peltz | Chief Executive Officer | Buy | 2,505.00 | 18.01 | 45,115.05 | 14,683.00 | |
| 2020-11-04 | Stuart Walter Peltz | Chief Executive Officer | Buy | 3,440.00 | 30.86 | 106,158.40 | 15,618.00 | |
| 2020-11-04 | Stuart Walter Peltz | Chief Executive Officer | Buy | 4,900.00 | 27.05 | 132,545.00 | 17,078.00 | |
| 2020-11-04 | Christine Marie Utter | SVP, Finance & CAO | Buy | 8,055.00 | 30.86 | 248,577.30 | 17,617.00 | |
| 2020-11-04 | Stuart Walter Peltz | Chief Executive Officer | Buy | 7,065.00 | 18.01 | 127,240.65 | 19,243.00 | |
| 2020-11-04 | Stuart Walter Peltz | Chief Executive Officer | Buy | 7,560.00 | 30.86 | 233,301.60 | 19,738.00 | |
| 2020-11-04 | Christine Marie Utter | SVP, Finance & CAO | Buy | 10,625.00 | 33.02 | 350,837.50 | 20,187.00 | |
| 2020-11-04 | Stuart Walter Peltz | Chief Executive Officer | Buy | 8,421.00 | 33.02 | 278,061.42 | 20,599.00 | |
| 2020-11-04 | Allan Steven Jacobson | Director | Buy | 20,000.00 | 10.85 | 217,000.00 | 23,498.00 | |
| 2020-11-04 | Neil Gregory Almstead | Chief Technical Ops Officer | Sell | 2,187.00 | 60.00 | 131,220.00 | 27,089.00 | |
| 2020-11-04 | Neil Gregory Almstead | Chief Technical Ops Officer | Buy | 2,187.00 | 11.23 | 24,560.01 | 29,276.00 | |
| 2020-11-04 | Allan Steven Jacobson | Director | Sell | 20,000.00 | 60.00 | 1,200,000.00 | 3,498.00 | |